<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="pmc-domain-id">2029</journal-id><journal-id journal-id-type="pmc-domain">bmri</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7695499</article-id><article-id pub-id-type="pmcid-ver">PMC7695499.1</article-id><article-id pub-id-type="pmcaid">7695499</article-id><article-id pub-id-type="pmcaiid">7695499</article-id><article-id pub-id-type="pmid">33274194</article-id><article-id pub-id-type="doi">10.1155/2020/1438928</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing <italic toggle="yes">Brucella</italic> Immunodominant Proteins in Mice and Guinea Pigs</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1891-2748</contrib-id><name name-style="western"><surname>Bugybayeva</surname><given-names initials="D">Dina</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6538-8486</contrib-id><name name-style="western"><surname>Ryskeldinova</surname><given-names initials="S">Sholpan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3536-5483</contrib-id><name name-style="western"><surname>Zinina</surname><given-names initials="N">Nadezhda</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0650-7457</contrib-id><name name-style="western"><surname>Sarmykova</surname><given-names initials="M">Makhpal</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7267-3931</contrib-id><name name-style="western"><surname>Assanzhanova</surname><given-names initials="N">Nurika</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9247-6273</contrib-id><name name-style="western"><surname>Kydyrbayev</surname><given-names initials="Z">Zhailaubay</given-names></name><email>kydyr2@mail.ru</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5823-1280</contrib-id><name name-style="western"><surname>Tabynov</surname><given-names initials="K">Kaissar</given-names></name><email>tabynov_81@mail.ru</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy 080409, Kazakhstan</aff><aff id="I2">
<sup>2</sup>Kazakh National Agrarian University, 8 Abay Avenue, Almaty 050010, Kazakhstan</aff><aff id="I3">
<sup>3</sup>Research Institute of Cardiology and Internal Medicine, 120 Aiteke bi, Almaty 050000, Kazakhstan</aff><author-notes><fn fn-type="other"><p>Academic Editor: Maxim Golovkin</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2020</year></pub-date><volume>2020</volume><issue-id pub-id-type="pmc-issue-id">350353</issue-id><elocation-id>1438928</elocation-id><history><date date-type="received"><day>1</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>11</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>02</day><month>12</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-12-04 16:56:20.947"><day>04</day><month>12</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 Dina Bugybayeva et al.</copyright-statement><copyright-year>2020</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BMRI2020-1438928.pdf"/><abstract><p>In this paper, we first used recombinant influenza viral vector (rIVV) subtype H5N1 expressing from the open reading frame of NS1 80 and NS1 124 amino acids of <italic toggle="yes">Brucella</italic> outer membrane proteins (Omp) 16 and 19, ribosomal L7/L12, and Cu-Zn superoxide dismutase (SOD) proteins to develop a human brucellosis vaccine. We made 18 combinations of IVVs in mono-, bi-, and tetravalent vaccine formulations and tested them on mice to select the safest and most effective vaccine samples. Then, the most effective vaccine candidates were further tested on guinea pigs. Safety of the rIVV-based vaccine candidate was evaluated by a mouse weight-gain test. Mice and guinea pigs were challenged with the virulent strain <italic toggle="yes">B. melitensis</italic> 16M. The protective effect of the rIVV-based vaccine candidate was assessed by quantitation of <italic toggle="yes">Brucella</italic> colonization in tissues and organs of challenged animals. All vaccine formulations were safe in mice. Tested vaccine formulations, as well as the commercial <italic toggle="yes">B. melitensis</italic> Rev.1 vaccine, have been found to protect mice from <italic toggle="yes">B. melitensis</italic> 16M infection within the range of 1.6 to 2.97 log<sub>10</sub> units (<italic toggle="yes">P</italic> &lt; 0.05). Tetravalent vaccine formulations from the position of NS1 80 amino acids (0.2 &#177; 0.4), as well as the commercial <italic toggle="yes">B. melitensis</italic> Rev.1 vaccine (1.2 &#177; 2.6), have been found to protect guinea pigs from <italic toggle="yes">B. melitensis</italic> 16M infection at a significant level (<italic toggle="yes">P</italic> &lt; 0.05). Thus, tetravalent vaccine formulation Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD was chosen as a potential vaccine candidate for further development of an effective human vaccine against brucellosis. These results show a promising future for the development of a safe human vaccine against brucellosis based on rIVVs.</p></abstract><funding-group><award-group><funding-source>Ministry of Education and Science of the Republic of Kazakhstan</funding-source><award-id>AP05131463</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Brucellosis is a zoonotic disease that is transmitted between species from animals to humans and is one of the most common infectious diseases in the world, with prevalence in developing countries. Annually, more than 500,000 new cases of human brucellosis are reported [<xref rid="B1" ref-type="bibr">1</xref>], and the main pathogenic Brucella species are <italic toggle="yes">B. abortus</italic>, <italic toggle="yes">B. melitensis</italic>, and <italic toggle="yes">B. suis</italic> [<xref rid="B2" ref-type="bibr">2</xref>]. Worldwide, <italic toggle="yes">B. melitensi</italic>s is the most prevalent and virulent species causing severe infections in humans [<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Due to economic and public health consequences of brucellosis in developing countries, efforts have been made to eradicate the disease through vaccination of the livestock sector, as high incidence of the disease in the human population is largely related to the high persistence level of the brucellosis infection in livestock [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Various vaccine strategies have been made to develop effective brucellosis vaccines with the majority of them intended for human use [<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>]. In particular, vector-based systems on the platform of attenuated viruses (Semliki Forest virus) or bacteria (<italic toggle="yes">Ochrobactrum anthropi</italic>, <italic toggle="yes">Yersinia enterocolitica</italic>, and <italic toggle="yes">Escherichia coli</italic>) have been developed and tested as vaccine candidates against brucellosis, including the presenting recombinant of <italic toggle="yes">Brucella</italic> proteins as Cu-Zn SOD, L7/L12, and Omp19 [<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B21" ref-type="bibr">21</xref>]. These vector platforms were tested predominantly in mouse models and induced vigorous Th1-type immune responses. In the majority of studies, protection was not confirmed against a challenge with virulent bacterial strain.</p><p>
<italic toggle="yes">Brucella</italic> antigens, such as outer membrane proteins (Omp) 16 and 19, ribosomal L7/L12, and Cu-Zn superoxide dismutase (SOD), are inducing a strong cell-mediated response required to clear the infection [<xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>]. However, a protective effect of a single epitope of immunization versus a mixed epitope vaccination is not very well understood yet.</p><p>The <italic toggle="yes">Brucella</italic> recombinant influenza viral vector- (IVV-) based vaccine Flu-BA has been developed previously and demonstrated efficacy in bovine comparable with the commercial <italic toggle="yes">B. abortus</italic> S19 vaccine [<xref rid="B25" ref-type="bibr">25</xref>]. The Flu-BA was registered in Kazakhstan in 2019 for vaccination of cattle against <italic toggle="yes">B. abortus</italic> infection. Bovine species, in general, are not a very susceptible host for influenza A viruses [<xref rid="B26" ref-type="bibr">26</xref>]. However, the influenza viral constructs can be more effective in developing a vaccine against human brucellosis, because influenza A is a frequent infection of humans. We believe that rIVV based on subtype H5N1 has more potential as a vaccine vector due to the lack of preexisting immunity to H5N1 in the general human population [<xref rid="B27" ref-type="bibr">27</xref>]. Accordingly, we utilized the rIVV of the H5N1 subtype inserted with <italic toggle="yes">Brucella</italic> antigens to develop a novel vaccine candidate against human brucellosis.</p><p>Thus, the purpose of this study was to select the most optimal vaccine constructs among the safest and protective rIVV expressing <italic toggle="yes">Brucella</italic> immonodominant proteins Omp16, Omp19, L7/L12, or SOD as a potential candidate for human vaccine development.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Generation of Virus Constructs and Preparation of Vaccine Samples</title><p>IVVs were obtained with the standard reverse genetic method utilizing 8 bidirectional plasmids pHW2000 [<xref rid="B28" ref-type="bibr">28</xref>]. In this study, we used eight monovalent vaccine constructs comprising the recombinant influenza A virus of the subtype H5N1 from the A/chicken/Astana/6/05 strain expressing the <italic toggle="yes">Brucella</italic> immunodominant proteins L7/L12, Omp16, Omp19, or Cu-Zn SOD containing a sequence of 80 or 124 N-terminal amino acids from the open reading frame (ORF) of the NS1 gene (HSC Development GmbH, Austria). A detailed procedure of rIVV generation is described previously [<xref rid="B29" ref-type="bibr">29</xref>]. Briefly, Vero cells were cotransfected by the Lonza Nucleofector&#8482; (Cologne, Germany) technique with plasmids encoding the PB1, PB2, PA, NP, and M genes and chimeric NS gene of the &#1040;/Puerto Rico/8/34 (H1N1) virus and the hemagglutinin (HA) and neuraminidase (NA) taken from the A/chicken/Astana/6/05 (H5N1) strain. Attenuation of the HA protein sequence of the H5 virus was provided by exchanging its polybasic cleavage site to one that included a trypsin-dependent sequence. The NS1 gene was modified to insert <italic toggle="yes">Brucella</italic> sequences. A sequence of 80 or 124 N-terminal amino acids from the NS protein paired with a sequence of <italic toggle="yes">Brucella</italic> proteins.</p><p>The obtained influenza vectors (Flu-NS1-80-Omp16, Flu-NS1-80-L7/L12, Flu-NS1-80-Omp19, Flu-NS1-80-SOD, Flu-NS1-124-Omp16, Flu-NS1-124-L7/L12, Flu-NS1-124-Omp19, and Flu-NS1-124-SOD) were then used for producing vaccine samples in 10-day-old embryonated chicken eggs (CE) as reported previously [<xref rid="B29" ref-type="bibr">29</xref>]. The insertion of referred <italic toggle="yes">Brucella</italic> proteins in the NS1 gene was confirmed by reverse transcription polymerase chain reaction (RT-PCR) Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">S1</xref>. Obtained allantoic fluid containing IVV inserted with various <italic toggle="yes">Brucella</italic> antigenic genes used as a mono formulation or pooled together in a 1&#8201;:&#8201;1 or 1&#8201;:&#8201;1&#8201;:&#8201;1&#8201;:&#8201;1 ratio to obtain overall 18 rIVV mono or combinations of bivalent and tetravalent formulations.</p></sec><sec id="sec2.2"><title>2.2. Bacterial Strains</title><p>The virulent strain of <italic toggle="yes">B. melitensis</italic> 16M, obtained from the Research Institute for Biological Safety Problem's (RIBSP) collection of microorganisms, was used in this study. The bacterial cells were cultured in <italic toggle="yes">Brucella</italic> base agar (Himedia Laboratories, India) under aerobic conditions at 37&#176;C. All laboratory experiments with live <italic toggle="yes">Brucella</italic> cells were conducted in biosafety level (BSL) 3. Challenged mice and guinea pigs were kept in animal BSL 3 facility.</p></sec><sec id="sec2.3"><title>2.3. Bioethics and Animal Groups</title><p>This study was carried out in accordance with the recommendations of the national and international guidelines on animal care and use. The study protocol was approved by the IACUC of the RIBSP (approval no. 0418/04). Animals were housed in a 12 light/12 dark cycle in cages under controlled environmental conditions and were fed <italic toggle="yes">ad libitum</italic> with standard rodent diet and had no water restrictions. Experimental and control groups of animals were kept in different rooms during the entire experiment. This study used male BALB/c mice (Charles River) aged 5-7 weeks old weighing 20-25&#8201;g and conventional bred female guinea pigs weighing 300-350&#8201;g (National Center for Expertise of Drugs, Medical Products and Equipment, Kazakhstan). By the randomization method, mice were divided into 20 groups (<italic toggle="yes">n</italic> = 12 per group): 18 experimental prime-boost groups, one negative PBS (phosphate-buffered saline) control group, and one positive control group. The guinea pigs were divided into 7 groups (<italic toggle="yes">n</italic> = 5 per group): five experimental prime-boost groups, one negative (PBS) control group, and one positive control group.</p></sec><sec id="sec2.4"><title>2.4. Immunization of Mice</title><p>Groups of mice in experimental prime-boost groups (<italic toggle="yes">n</italic> = 5 or <italic toggle="yes">n</italic> = 12 per group) for safety or challenge studies were injected peritoneally (<italic toggle="yes">i.p.</italic>) twice with prepared vector brucellosis vaccine formulations (18 overall) at an interval of 14 or 21 days. After selection of mice within these 18 formulations, 5 vaccine formulations that demonstrated significant results were further tested on guinea pigs with the same prime-boost immunization scheme when rIVV was administered intranasally (<italic toggle="yes">i.n.</italic>) twice with an interval of 21 days between vaccinations. The animal immunization scheme is presented in <xref rid="tab1" ref-type="table">Table 1</xref>. Mice and guinea pigs from the positive control groups were injected subcutaneously (<italic toggle="yes">s.c.</italic>) with the <italic toggle="yes">B. melitensis</italic> Rev.1 (Antigen LLP, Kazakhstan) only once at a dose of 6.0 log<sub>10</sub> CFU/animal. Mice and guinea pigs of the negative control groups <italic toggle="yes">s.c.</italic> injected with 200&#8201;<italic toggle="yes">&#956;</italic>l of PBS.</p></sec><sec id="sec2.5"><title>2.5. Assessment of Mono-, Bi-, and Tetravalent Vaccine Formulation Safety</title><p>To assess the safety of vaccine samples (or their level of attenuation), vaccinated mouse body weight changes were monitored daily for 28 days after both prime and booster vaccinations with viral constructs or <italic toggle="yes">B. melitensis</italic> Rev.1 (vaccination was provided only once) and compared to the negative (PBS) control group. General observation for safety was evaluated by animal survival and animals' general condition, behavior, and dynamics of body weight change.</p></sec><sec id="sec2.6"><title>2.6. Assessment of the Vaccine Formulation's Protectiveness in Mice and Guinea Pigs</title><p>In order to evaluate vaccine formulation's protectiveness, mice from the experimental vaccine groups (<italic toggle="yes">n</italic> = 5 per group) and PBS injected control group (<italic toggle="yes">n</italic> = 5) were challenged <italic toggle="yes">i.p.</italic> with the virulent strain of <italic toggle="yes">B. melitensis</italic> 16M in a dose of 6.0 log<sub>10</sub> CFU/animal on 21 days after the boost vaccination. Mice in the positive control group (<italic toggle="yes">n</italic> = 5) were immunized with the vaccine <italic toggle="yes">B. melitensis</italic> Rev.1 and challenged on day 42. On day 14 postchallenge, all animals were sacrificed by CO<sub>2</sub> asphyxiation to collect spleen tissues aseptically for bacteriological studies. The spleen from each animal was harvested and homogenized in 5&#8201;ml of 0.1% Triton-PBS, and 100&#8201;<italic toggle="yes">&#956;</italic>l of 10-fold serial dilutions of spleen suspension was plated in triplicate onto <italic toggle="yes">Brucella</italic> base agar (HiMedia Laboratories, India) plates. Plates were incubated at 37&#176;C for 2 weeks, and the number of bacterial colony growth was counted periodically by performing standard plate counts to determine the concentration of bacteria (CFU/tissue) in spleens. An animal was considered to be infected if one or more <italic toggle="yes">Brucella</italic> colonies were present in the cultures. The protective effect of the vaccine samples was assessed by comparing the degree of spleen infection of vaccinated experimental and reference control groups and unvaccinated control group after virulence challenge with <italic toggle="yes">B. melitensis</italic> 16M (expressed as log<sub>10</sub> CFU/g of tissue protection unit).</p><p>After studying the protective efficacy of vaccine formulations, the five most protective vaccine formulations were assessed in the guinea pig model. The challenge study for guinea pigs was similar as what was done for mice, and it was consistent based on route of infection, grouping of animals, preparing suspension from animal organs, bacteria growing conditions, and counting of colonies. Twenty-one days after the boost vaccination, guinea pigs from the experimental groups (<italic toggle="yes">n</italic> = 25), PBS control (<italic toggle="yes">n</italic> = 5), and positive control (<italic toggle="yes">n</italic> = 5) (on day 42 after prime vaccination with vaccine <italic toggle="yes">B. melitensis</italic> Rev.1) groups were challenged <italic toggle="yes">s.c.</italic> with the virulent strain of <italic toggle="yes">B. melitensis</italic> 16M in a dose of 1.3 log<sub>10</sub> CFU/animal. Thirty days after challenge, animals from all groups were euthanized and aseptically dissected to collect the following tissues: retropharyngeal, lower cervical, right and left inguinal lymph nodes, liver, spleen, and bone marrow. The results of the bacteriological assessment were evaluated from three parameters, including vaccination efficacy (expressed in %) determined as the number of animals from which no colonies were isolated, infection index (number of tissues from which <italic toggle="yes">Brucella</italic> were isolated in), and protective efficacy evaluated as the degree of <italic toggle="yes">Brucella</italic> colonization in organs and lymph nodes expressed as log<sub>10</sub> CFU/g of tissue.</p></sec><sec id="sec2.7"><title>2.7. Statistical Analysis</title><p>The safety of vaccine formulations was analyzed using one-way ANOVA (Dunnett's multiple comparison test). Protection of vaccines and index of infection data were analyzed with a one-way ANOVA (Tukey's multiple comparison test) and two-way ANOVA (Sidak's multiple comparison test), respectively. The variance in protective efficacy of animal groups was compared by one-sided Fisher exact test. <italic toggle="yes">P</italic> values &lt; 0.05 were considered significant. Means are reported with standard errors (SEM) and 95% confidence interval. Statistical analysis was performed with GraphPad Prism Software, version 6.0 (GraphPad Software Inc., La Jolla, CA, USA). The experiments have been repeated, and the results were reproducible.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Assessment of Various Vaccine Formulations' Safety in Mice</title><p>The safety or degree of attenuation of various vaccine formulations, comprising mono-, bi-, or tetravalent rIVV, were determined in mice in comparison with the positive (<italic toggle="yes">B. melitensis</italic> 16M) and negative (PBS) control groups. It was found that all vaccine samples, including <italic toggle="yes">B. melitensis</italic> Rev.1, were safe in mice after <italic toggle="yes">i.p.</italic> injection. No animal death or disease sign was observed in any group by the end of the observation period. Overall, condition of animals both in the control and experimental groups was moderate, in terms of physical activity, appetite, and general outward condition.</p><p>Assessment of percent change of body weight over 28 days upon prime or boost immunizations showed an increase in the animals' body weight for all type of viral construct (<xref ref-type="fig" rid="fig1">Figure 1</xref>). By the end of the observation period, the weight of mice in the experimental groups has been increased by 19-29% or 3.8-5.8&#8201;g, which was similar to the control group&#8212;28% or 4.7&#8201;g. No group was significantly different in mean of body weight from the PBS-treated control group (<italic toggle="yes">P</italic> &gt; 0.5).</p><p>It should be noted that examination of the <italic toggle="yes">Brucella</italic> proteins in the NS1 gene by the RT-PCR confirmed that all the viral constructs retained their corresponding <italic toggle="yes">Brucella</italic> inserts upon producing rIVV in CE.</p></sec><sec id="sec3.2"><title>3.2. Protectiveness of Vaccine Formulations in Mice against <italic toggle="yes">B. melitensis</italic> 16M Infection</title><p>This experiment was conducted to assess protective efficacy of 18 mono-, bi-, or tetravalent vaccine formulations first in a mouse model to determine the most protective vaccine formulations against <italic toggle="yes">B. melitensis</italic> 16M infection and to compare to the reference <italic toggle="yes">B. melitensis</italic> Rev.1 vaccine group or PBS control group. The protective activity of the vaccines was evaluated by bacterial load or virulent <italic toggle="yes">Brucella</italic> bacteria colonization in spleens of vaccinated and nonvaccinated animals. The results of the bacteriology study after the virulence challenge showed that mono-, bi-, or tetravalent vaccine formulations as well as <italic toggle="yes">B. melitensis</italic> Rev.1 provided protection between 1.6 and 2.79 log<sub>10</sub> units. Compared to the PBS unvaccinated control group, all vaccine formulations as well as the commercial vaccine provided protection of mice from <italic toggle="yes">B. melitensis</italic> 16M infection on rates of virulent strain colonization in challenged animal spleens (<xref rid="tab2" ref-type="table">Table 2</xref>).</p><p>Significant protection in comparison with the PBS control group was achieved in the following 5 groups: (1) 80-Omp16, (8) 124-Cu-Zn-SOD, (13) 80-Omp16+L7/L12+Omp19+Cu-Zn-SOD, (16)124-Omp16+Omp19, and (18) 124-Omp16+L7/L12+Omp19+Cu-Zn-SOD (<italic toggle="yes">P</italic> &lt; 0.02) as well as in the positive control group vaccinated with <italic toggle="yes">B. melitensis</italic> Rev.1 (<italic toggle="yes">P</italic> &lt; 0.02). By the result of this study, the five most protective vaccine formulations that showed significant results in mice were continued in guinea pigs to confirm an efficacy of selected vaccine formulations.</p></sec><sec id="sec3.3"><title>3.3. Assessing of Protection of Five Vaccine Formulations in Guinea Pigs</title><p>From the 18 vaccine formulations assessed in mice, the five most protective ones were further investigated in a guinea pig model. The protective efficacy of viral vectors expressing immunodominant <italic toggle="yes">Brucella</italic> proteins Omp16, L7/L12, Omp19, and SOD at mono-, bi-, or tetravalent vaccine formulations was compared to that of a commercial vaccine <italic toggle="yes">B. melitensis</italic> Rev.1 and PBS and assessed by parameters, such as colonization of the virulent strain of <italic toggle="yes">B. melitensis</italic> 16M in the lymph nodes and organs of the vaccinated and unvaccinated animals and index of infection (number of tissues and organs from which <italic toggle="yes">Brucella</italic> bacteria were isolated). All vaccine formulations and the commercial vaccine provided significant protection (<italic toggle="yes">P</italic> &lt; 0.01&#8211;<italic toggle="yes">P</italic> &lt; 0.0001 compared to the PBS control group) to the guinea pigs against the virulent strain <italic toggle="yes">B. melitensis</italic> 16M to a certain degree, specifically in the number of cultured <italic toggle="yes">Brucella</italic> in tissues and organs of animals upon the challenge. In animals vaccinated with 80-Omp16+L7/L12+Omp19+SOD (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>, average value for the group: 0.01 log<sub>10</sub> CFU/g of tissue) and 124-Omp16+L7/L12+Omp19+SOD (average value for group: 1.01 log<sub>10</sub> CFU/g of tissue), we found a low degree of <italic toggle="yes">Brucella</italic> colonization in tissues (for the NS1-80 tetravalent group only in the spleen) in comparison with the PBS control group (2.9 log<sub>10</sub> CFU/g of tissue).</p><p>According to the index of infection (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>), a significant level of protection in comparison with the control challenge group (the infection rate, 100%) was achieved in the group that was vaccinated with the tetravalent viral construct (<italic toggle="yes">P</italic> &lt; 0.01; vaccination efficacy, 80%) expressing the <italic toggle="yes">Brucella</italic> Omp16, L7/L12, Omp19, and SOD proteins fused to the N-terminal 80 amino acids of NS1. It is worth noting that although in the animal group vaccinated with <italic toggle="yes">B. melitensis</italic> Rev.1, the effectiveness of vaccination (<xref rid="tab3" ref-type="table">Table 3</xref>) reached 80% (<italic toggle="yes">P</italic> = 0.02); however, the index of infection for the <italic toggle="yes">B. melitensis</italic> Rev.1 group was not significantly different from that for the groups vaccinated with the above-mentioned tetravalent viral constructs.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The available commercial vaccines against brucellosis are limited to use just in small ruminants and cattle because of the adverse effect of these vaccines for human use [<xref rid="B30" ref-type="bibr">30</xref>]. The search for safe and effective human brucellosis vaccines remains active today, specifically for farmers in endemic places as well as for veterinarians with risks related to the occupational exposure and animal care workers [<xref rid="B31" ref-type="bibr">31</xref>]. Numerous candidate vaccines and vaccine strategies against <italic toggle="yes">B. abortus</italic> have been evaluated in animal models, including DNA vaccine, recombinant subunit peptide, protein, LPS, outer membrane vesicles (OMV), a live vector (viral or bacterial vector-based <italic toggle="yes">Brucella</italic> vaccines), combinations in prime and boost strategies, and others. <italic toggle="yes">Brucella</italic> recombinant vaccinia viruses expressing L7/L12, Omp18, and GroEL proteins have been studied in mouse models without substantial protection against <italic toggle="yes">Brucella</italic> challenge [<xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B34" ref-type="bibr">34</xref>]. Highly immunogenic constructs have been developed based on an adenoviral vector expressing both p39 and lumazine synthase proteins of <italic toggle="yes">B. abortus</italic> [<xref rid="B35" ref-type="bibr">35</xref>]. However, preexisting immunity to the viral vector could prevent a vaccine from working. To circumvent the problem of preexisting immunity, nonhuman adenovirus vectors or genetically modified adenovirus constructs could be used as the vaccine carrier. Replication-deficient <italic toggle="yes">Semliki Forest</italic> virus expressing <italic toggle="yes">Brucella</italic> translation initiation factor 3 (IF3) and Sod C generated some Th1 response and partial protection in mice [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. Influenza viruses expressing <italic toggle="yes">Brucella</italic> ribosomal proteins L7/L12 and Omp16 produced a long-term protection in pregnant heifers against <italic toggle="yes">B. abortus</italic> infection [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>]. As reported previously, immunization with <italic toggle="yes">B. abortus</italic> recombinant influenza A viruses based on subtypes H5N1 or H1N1 was protective in cattle [<xref rid="B38" ref-type="bibr">38</xref>]. However, bovines are naturally immune to influenza infections. We reasoned if we could generate protection in mouse and guinea pig models using improved <italic toggle="yes">Brucella</italic> antigen composition in influenza A viruses based on subtypes H5N1 as vaccine career, then we can potentially use these recombinant vaccines for preclinical and clinical trials in humans.</p><p>There is absence or little preexisting immunity against influenza virus A of subtype H5N1 in the human population. This is an important conceptual basis and quality of our vaccine vector candidates for future <italic toggle="yes">Brucella</italic> vaccine development in humans. We used a previously generated backlog of viral constructs, specifically 8 IVV of subtype H5N1 expressing Omp16, L7/L12, Omp19, and Cu-Zn SOD inserted into the NS1 gene region at position 80 or 124 amino acids. From these viral constructs were formed 18 vaccine formulations to characterize their safety and protection in mice and guinea pigs to form the final vaccine formulation. As the vaccine intended for use in humans, placing outbred animals (BALB/c mice) and a less homogeneous population of guinea pigs should demonstrate relationship in consistency and performance.</p><p>In the present study, we used intraperitoneal (<italic toggle="yes">i.p.</italic>) inoculation of rIVV in the prime-boost immunization strategy in mice and intranasal (<italic toggle="yes">i.n.</italic>) administration in the guinea pig model. Animals in the control group have been vaccinated with commercial <italic toggle="yes">B. melitensis</italic> Rev.1 <italic toggle="yes">s.c.</italic> by the manufacturer's recommendations. For this study, the influenza A viral vector was generated on the backbone of the NS (chimeric) gene of Puerto Rico/8/34 (H1N1), and the surface genes for hemagglutinin and neuraminidase were taken from A/chicken/Astana/6/05 (H5N1) strain. The PR8 virus is a mouse-adapted virus with efficient replicative properties in mice that could cause an infectious process in mouse lungs and lead to mortality when delivered <italic toggle="yes">i.n.</italic> [<xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B43" ref-type="bibr">43</xref>]. Therefore, we used <italic toggle="yes">i.p.</italic> inoculation of vaccine samples in mice due to the nature of the PR8 virus to cause disease symptoms.</p><p>As the influenza virus has tropism to mucosal surfaces, we believe that the optimal way for rIVV immunization is the <italic toggle="yes">i.n.</italic> route. Bearing in mind that <italic toggle="yes">Brucella</italic> should be considered as a mucosal pathogen, penetrating the mucosa of the nasal or oral cavities after ingestion, mucosal vaccination is capable of generating protective responses against pathogens at the mucosal site of entry [<xref rid="B44" ref-type="bibr">44</xref>].</p><p>Safety or attenuation of rIVV conferred by the shortened NS1 gene that facilitates their limited replicative ability [<xref rid="B29" ref-type="bibr">29</xref>]. We found that all vaccine formulations were safe, and no animal death or weight decrease was observed in mice. Additionally, after the challenge study in mice, we took five effective vaccine formulations and used them for <italic toggle="yes">i.n.</italic> immunization of guinea pigs. Importantly, bacteriological studies in mice demonstrated that that rIVV-based vaccine formulations demonstrated a similar level of protection as commercially established vaccine <italic toggle="yes">B. melitensis</italic> Rev.1. These data were reproducible in the guinea pig model as well. Thus, we concluded that rIVV vaccine formulations were as effective as the commercial vaccine. Formulations coding amino acids at positions 80 or 124, especially tetravalent constructs, in protection studies demonstrated results similar to those of the group vaccinated with the commercial vaccine. In addition, protective efficacy and immunogenicity of the candidate vaccine were established through a standardized challenge study by the ability of an animal model to restrain bacteria in the spleen [<xref rid="B45" ref-type="bibr">45</xref>].</p><p>To our knowledge, this is the first study to utilize a <italic toggle="yes">Brucella</italic> recombinant vector coding 80 amino acids at ORF of the NS1 for protective studies in animal models. For development of a human vaccine, NS1-80 may have some advantages. Knowing interferon antagonist properties of the influenza NS1 protein, viral constructs with a length of NS1-80 amino acid size should be less aggressive than NS-124, which has a half-length of the NS1. There is some correlation between length of the NS1 protein and attenuation of the virus in live organisms [<xref rid="B46" ref-type="bibr">46</xref>]. Because IVV has a different infectivity based on the length of the NS1 protein, combined use of IVV with different lengths of the NS1 protein (80 and 124) can lead to the interference of individual viruses, which is not observed when using IVV with the same length of NS1 protein.</p><p>There are some concerns in general about using IVV of subtype H5N1, which is a pathogenic type of influenza virus circulated in birds. Major concerns related to interspecies transmission of the disease from bird to human may cause diseases in the human population. However, in our case, the virus has proven to be attenuated through removal of the proteolytic cleavage site in the HA, and safety of the rIVV is ensured through the shortened NS1 gene, and as the result, they have limiting replicative ability [<xref rid="B29" ref-type="bibr">29</xref>]. Another risk related to using rIVV to public health is generation of reassortment between avian H5N1 and human influenza viruses that might confer pandemic strains [<xref rid="B47" ref-type="bibr">47</xref>]. However, for more than 30 years of using live attenuated cold-adapted influenza virus vaccine for humans, there are no records to date of a new emergence of virulent reassortants [<xref rid="B48" ref-type="bibr">48</xref>]. This vaccine candidate is not intended for mass vaccination and will be used for people in the risk groups only. Our previous studies have demonstrated that after repeated passages in CE, the IVV retained its main biological properties, including attenuation, and did not lose <italic toggle="yes">Brucella</italic> antigen inserts [<xref rid="B29" ref-type="bibr">29</xref>], indicating their genetic stability. In addition, the IVV belong to the group of RNA viruses, which facilitates the limiting replicative process that eliminates the risk of integration and long-term persistence.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>Thus, the results of this study demonstrated that recombinant influenza virus subtype A/H5N1 expressing the <italic toggle="yes">Brucella</italic> L7/L12 or Omp16 or Omp19 or Cu-Zn SOD (SOD) proteins from the open reading frame (ORF) of the NS1 gene in combination with tetravalent formulations is a safe vector, and its protectiveness against <italic toggle="yes">B. melitensis</italic> 16&#1052; infection in the prime-boost regimen is comparable to the <italic toggle="yes">B. melitensis</italic> Rev.1 commercial vaccine in mouse and guinea pig models. This study is a substantial step for the development of a safe and protective human brucellosis vaccine.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors express their gratitude to B. Yespembetov, Y. Kozhamkulov, and D. Inkarbekov, employees of the Research Institute for Biological Safety Problems, for their assistance in the present study. This work was supported by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (Grant No. AP05131463).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>All datasets generated for this study are included in the article/supplementary material.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>No potential conflict of interest was reported by the authors.</p></sec><sec><title>Authors' Contributions</title><p>KT and ShR planned and designed the present work. NZ, ShR, DB, NA (in guinea pig model), and MS were responsible for realizing the work. DB and KT were responsible for the data acquision and analysis. DB drafted and revised the manuscript. KT and ZhK approved the final version of the manuscript. All authors read and approved the final manuscript. ZhK and KT contributed equally to this work and are corresponding authors.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="supp-1" position="float" orientation="portrait"><label>Supplementary Materials</label><caption><p>Figure S1: insertion of Brucella proteins in the NS1 gene as determined by RT-PCR upon accumulation in CE.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1438928.f1.pptx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gali&#324;ska</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Zag&#243;rski</surname><given-names>J.</given-names></name></person-group><article-title>Brucellosis in humans-etiology, diagnostics, clinical forms</article-title><source><italic toggle="yes">Annals of Agricultural and Environmental Medicine</italic></source><year>2013</year><volume>20</volume><issue>2</issue><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">23772567</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akritidis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bosilkovski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsianos</surname><given-names>E.</given-names></name></person-group><article-title>Brucellosis</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>22</issue><fpage>2325</fpage><lpage>2336</lpage><pub-id pub-id-type="doi">10.1056/nejmra050570</pub-id><pub-id pub-id-type="other">2-s2.0-19644363222</pub-id><pub-id pub-id-type="pmid">15930423</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Legesse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edao</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Ameni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mamo</surname><given-names>G.</given-names></name></person-group><article-title>Isolation and identification of Brucella melitensis using bacteriological and molecular tools from aborted goats in the Afar region of North-Eastern Ethiopia</article-title><source><italic toggle="yes">BMC Microbiology</italic></source><year>2019</year><volume>19</volume><issue>1</issue><fpage>p. 108</fpage><pub-id pub-id-type="doi">10.1186/s12866-019-1474-y</pub-id><pub-id pub-id-type="other">2-s2.0-85066847740</pub-id><pub-id pub-id-type="pmid">31126230</pub-id><pub-id pub-id-type="pmcid">PMC6534919</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z. F.</given-names></name></person-group><article-title>Establishment of chronic infection: Brucella's stealth strategy</article-title><source><italic toggle="yes">Frontiers in Cellular and Infection Microbiology</italic></source><year>2016</year><volume>6</volume><issue>30</issue><pub-id pub-id-type="doi">10.3389/fcimb.2016.00030</pub-id><pub-id pub-id-type="other">2-s2.0-85006207101</pub-id><pub-id pub-id-type="pmcid">PMC4791395</pub-id><pub-id pub-id-type="pmid">27014640</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalsiamthara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name></person-group><article-title>Development and trial of vaccines against Brucella</article-title><source><italic toggle="yes">Journal of Veterinary Science</italic></source><year>2017</year><volume>18</volume><issue>S1</issue><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.4142/jvs.2017.18.S1.281</pub-id><pub-id pub-id-type="other">2-s2.0-85027964692</pub-id><pub-id pub-id-type="pmid">28859268</pub-id><pub-id pub-id-type="pmcid">PMC5583415</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Skyberg</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clapp</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>D. W.</given-names></name></person-group><article-title>Progress in Brucella vaccine development</article-title><source><italic toggle="yes">Frontiers in Biology</italic></source><year>2013</year><volume>8</volume><issue>1</issue><fpage>60</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s11515-012-1196-0</pub-id><pub-id pub-id-type="other">2-s2.0-84873187485</pub-id><pub-id pub-id-type="pmid">23730309</pub-id><pub-id pub-id-type="pmcid">PMC3666581</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Smither</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>H. S.</given-names></name></person-group><article-title>Towards a Brucella vaccine for humans</article-title><source><italic toggle="yes">FEMS Microbiology Reviews</italic></source><year>2010</year><volume>34</volume><issue>3</issue><fpage>379</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2010.00211.x</pub-id><pub-id pub-id-type="other">2-s2.0-77950380555</pub-id><pub-id pub-id-type="pmid">20180858</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tibor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2001</year><volume>69</volume><issue>8</issue><fpage>4816</fpage><lpage>4822</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.8.4816-4822.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0034927083</pub-id><pub-id pub-id-type="pmid">11447155</pub-id><pub-id pub-id-type="pmcid">PMC98569</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Elzer</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Hagius</surname><given-names>S. D.</given-names></name><etal/></person-group><article-title>Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2006</year><volume>24</volume><issue>24</issue><fpage>5169</fpage><lpage>5177</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.005</pub-id><pub-id pub-id-type="other">2-s2.0-33744526889</pub-id><pub-id pub-id-type="pmid">16697090</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salmakov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plumb</surname><given-names>G.</given-names></name></person-group><article-title>A live vaccine from Brucella abortus strain 82 for control of cattle brucellosis in the Russian Federation</article-title><source><italic toggle="yes">Animal Health Research Reviews</italic></source><year>2011</year><volume>12</volume><issue>1</issue><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1017/S1466252311000028</pub-id><pub-id pub-id-type="other">2-s2.0-80055067006</pub-id><pub-id pub-id-type="pmid">21676343</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Merino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asselineau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Serre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bascoul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lacave</surname><given-names>C.</given-names></name></person-group><article-title>Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>1976</year><volume>13</volume><issue>2</issue><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1128/IAI.13.2.311-321.1976</pub-id><pub-id pub-id-type="pmid">770324</pub-id><pub-id pub-id-type="pmcid">PMC420613</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Iba&#241;ez</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Coria</surname><given-names>L. M.</given-names></name><etal/></person-group><article-title>An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2011</year><volume>6</volume><issue>1, article e16203</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0016203</pub-id><pub-id pub-id-type="other">2-s2.0-79251592270</pub-id><pub-id pub-id-type="pmid">21264260</pub-id><pub-id pub-id-type="pmcid">PMC3021544</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpino</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Estein</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J.</given-names></name></person-group><article-title>Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2007</year><volume>25</volume><issue>37-38</issue><fpage>6721</fpage><lpage>6729</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.8.4816-4822.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0034927083</pub-id><pub-id pub-id-type="pmid">17686554</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>J.</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>G.</given-names></name></person-group><article-title>Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2012</year><volume>30</volume><issue>27</issue><fpage>4017</fpage><lpage>4022</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.036</pub-id><pub-id pub-id-type="other">2-s2.0-84861480849</pub-id><pub-id pub-id-type="publisher-id">PMC3361596</pub-id><pub-id pub-id-type="pmid">22546330</pub-id><pub-id pub-id-type="pmcid">PMC3361596</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>G. G.</given-names></name></person-group><article-title>Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2002</year><volume>70</volume><issue>5</issue><fpage>2535</fpage><lpage>2543</lpage><pub-id pub-id-type="doi">10.1128/iai.70.5.2535-2543.2002</pub-id><pub-id pub-id-type="other">2-s2.0-0036122025</pub-id><pub-id pub-id-type="pmid">11953393</pub-id><pub-id pub-id-type="pmcid">PMC127893</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;ez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#324;ate</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2008</year><volume>129</volume><issue>3-4</issue><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2007.11.015</pub-id><pub-id pub-id-type="other">2-s2.0-43049166972</pub-id><pub-id pub-id-type="pmid">18164561</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salgado</surname><given-names>P.</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A.</given-names></name></person-group><article-title>Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide-dismutase: II. Induction of specific CD8+ cytotoxic lymphocytes and sensitized CD4+ IFN-gamma-producing cell</article-title><source><italic toggle="yes">Microbiology and Immunology</italic></source><year>2006</year><volume>50</volume><issue>5</issue><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1111/j.1348-0421.2006.tb03805.x</pub-id><pub-id pub-id-type="other">2-s2.0-33646855243</pub-id><pub-id pub-id-type="pmid">16714846</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harms</surname><given-names>J. S</given-names></name><name name-style="western"><surname>Durward</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>G. A.</given-names></name></person-group><article-title>Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella</article-title><source><italic toggle="yes">Journal of Immune Based Therapies and Vaccines</italic></source><year>2009</year><volume>7</volume><issue>1</issue><fpage>p. 1</fpage><pub-id pub-id-type="doi">10.1186/1476-8518-7-1</pub-id><pub-id pub-id-type="other">2-s2.0-61349162436</pub-id><pub-id pub-id-type="publisher-id">PMC2633335</pub-id><pub-id pub-id-type="pmid">19126207</pub-id><pub-id pub-id-type="pmcid">PMC2633335</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2009</year><volume>27</volume><issue>38</issue><fpage>5214</fpage><lpage>5219</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.075</pub-id><pub-id pub-id-type="other">2-s2.0-67651100867</pub-id><pub-id pub-id-type="pmid">19596411</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;ez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A.</given-names></name></person-group><article-title>Oral immunization of mice with recombinant Lactococcus lactis expressing Cu,Zn superoxide dismutase of Brucella abortus triggers protective immunity</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2012</year><volume>30</volume><issue>7</issue><fpage>1283</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.088</pub-id><pub-id pub-id-type="other">2-s2.0-84856568820</pub-id><pub-id pub-id-type="pmid">22222868</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#241;ate</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H.</given-names></name></person-group><article-title>Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>1999</year><volume>67</volume><issue>2</issue><fpage>986</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.2.986-988.1999</pub-id><pub-id pub-id-type="pmid">9916121</pub-id><pub-id pub-id-type="pmcid">PMC96417</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Estein</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Samartino</surname><given-names>C. G.</given-names></name><etal/></person-group><article-title>Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2009</year><volume>77</volume><issue>1</issue><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1128/IAI.01151-08</pub-id><pub-id pub-id-type="other">2-s2.0-58449120792</pub-id><pub-id pub-id-type="pmid">18981242</pub-id><pub-id pub-id-type="pmcid">PMC2612246</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Steitz</surname><given-names>T. A.</given-names></name></person-group><article-title>Ribosomal protein L7/L12 has a helix-turn-helix motif similar to that found in DNA-binding regulatory proteins</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>1989</year><volume>17</volume><issue>10</issue><fpage>3757</fpage><lpage>3762</lpage><pub-id pub-id-type="doi">10.1093/nar/17.10.3757</pub-id><pub-id pub-id-type="other">2-s2.0-0024377959</pub-id><pub-id pub-id-type="pmid">2660100</pub-id><pub-id pub-id-type="pmcid">PMC317856</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz-Montesino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rivers</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2004</year><volume>72</volume><issue>4</issue><fpage>2081</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1128/iai.72.4.2081-2087.2004</pub-id><pub-id pub-id-type="other">2-s2.0-12144291024</pub-id><pub-id pub-id-type="pmid">15039330</pub-id><pub-id pub-id-type="pmcid">PMC375181</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabynov</surname><given-names>K.</given-names></name></person-group><article-title>Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2016</year><volume>15</volume><issue>10</issue><fpage>1237</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1208089</pub-id><pub-id pub-id-type="other">2-s2.0-84978035461</pub-id><pub-id pub-id-type="pmid">27356589</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sreenivasan</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Influenza A in bovine species: a narrative literature review</article-title><source><italic toggle="yes">Viruses</italic></source><year>2019</year><volume>11</volume><issue>6</issue><fpage>p. 561</fpage><pub-id pub-id-type="doi">10.3390/v11060561</pub-id><pub-id pub-id-type="other">2-s2.0-85068436643</pub-id><pub-id pub-id-type="pmid">31213032</pub-id><pub-id pub-id-type="pmcid">PMC6631717</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hien</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>J.</given-names></name></person-group><article-title>Avian influenza-a challenge to global health care structures</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2004</year><volume>351</volume><issue>23</issue><fpage>2363</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.1056/nejmp048267</pub-id><pub-id pub-id-type="other">2-s2.0-16544364998</pub-id><pub-id pub-id-type="pmid">15575048</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kawaoka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hobom</surname><given-names>G.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R. G.</given-names></name></person-group><article-title>A DNA transfection system for generation of influenza A virus from eight plasmids</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2000</year><volume>97</volume><issue>11</issue><fpage>6108</fpage><lpage>6113</lpage><pub-id pub-id-type="doi">10.1073/pnas.100133697</pub-id><pub-id pub-id-type="other">2-s2.0-0034705225</pub-id><pub-id pub-id-type="pmid">10801978</pub-id><pub-id pub-id-type="pmcid">PMC18566</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabynov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sansyzbay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kydyrbayev</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2014</year><volume>11</volume><issue>1</issue><fpage>p. 69</fpage><pub-id pub-id-type="doi">10.1186/1743-422x-11-69</pub-id><pub-id pub-id-type="other">2-s2.0-84899586125</pub-id><pub-id pub-id-type="pmid">24716528</pub-id><pub-id pub-id-type="pmcid">PMC3997475</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N.</given-names></name><name name-style="western"><surname>V</surname><given-names>M. J.</given-names></name></person-group><article-title>Brucellosis vaccines: past, present and future</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>90</volume><issue>1-4</issue><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/s0378-1135(02)00255-9</pub-id><pub-id pub-id-type="other">2-s2.0-0037146685</pub-id><pub-id pub-id-type="pmid">12414166</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zinsstag</surname><given-names>J.</given-names></name><name name-style="western"><surname>Orkhon</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Human health benefits from livestock vaccination for brucellosis: case study</article-title><source><italic toggle="yes">Bulletin of the World Health Organization</italic></source><year>2003</year><volume>81</volume><issue>12</issue><fpage>867</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">14997239</pub-id><pub-id pub-id-type="pmcid">PMC2572379</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baloglu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S.</given-names></name></person-group><article-title>Humoral immune response of BALB/c mice to a vaccinia virus recombinant expressing Brucella abortus GroEL does not correlate with protection against a B. abortus challenge</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2000</year><volume>76</volume><issue>2</issue><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/s0378-1135(00)00231-5</pub-id><pub-id pub-id-type="other">2-s2.0-0034715321</pub-id><pub-id pub-id-type="pmid">10946149</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baloglu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>T. E.</given-names></name></person-group><article-title>Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2005</year><volume>109</volume><issue>1-2</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2005.04.011</pub-id><pub-id pub-id-type="other">2-s2.0-21744455459</pub-id><pub-id pub-id-type="pmid">15941627</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cravero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>C. L.</given-names></name><etal/></person-group><article-title>Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus</article-title><source><italic toggle="yes">Clinical and Diagnostic Laboratory Immunology</italic></source><year>2000</year><volume>7</volume><issue>1</issue><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1128/cdli.7.1.114-118.2000</pub-id><pub-id pub-id-type="pmid">10618289</pub-id><pub-id pub-id-type="pmcid">PMC95834</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>G. Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z. R.</given-names></name></person-group><article-title>Immunogenicity of adenovirus and DNA vaccines co-expressing P39 and lumazine synthase proteins of Brucella abortus in BALB/c mice</article-title><source><italic toggle="yes">Tropical Animal Health and Production</italic></source><year>2018</year><volume>50</volume><issue>5</issue><fpage>957</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1007/s11250-018-1517-7</pub-id><pub-id pub-id-type="other">2-s2.0-85042593401</pub-id><pub-id pub-id-type="pmid">29492808</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>D.</given-names></name><name name-style="western"><surname>C&#233;spedes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A.</given-names></name></person-group><article-title>Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice</article-title><source><italic toggle="yes">Immunobiology</italic></source><year>2009</year><volume>214</volume><issue>6</issue><fpage>467</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2008.11.016</pub-id><pub-id pub-id-type="other">2-s2.0-64649085570</pub-id><pub-id pub-id-type="pmid">19150742</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onate</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Donoso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moraga-Cid</surname><given-names>G.</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H.</given-names></name><name name-style="western"><surname>C&#233;spedes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E.</given-names></name></person-group><article-title>An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu, Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2005</year><volume>73</volume><issue>6</issue><fpage>3294</fpage><lpage>3300</lpage><pub-id pub-id-type="doi">10.1128/iai.73.6.3294-3300.2005</pub-id><pub-id pub-id-type="other">2-s2.0-19744374114</pub-id><pub-id pub-id-type="pmid">15908354</pub-id><pub-id pub-id-type="pmcid">PMC1111843</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabynov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kydyrbayev</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ryskeldinova</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2014</year><volume>32</volume><issue>18</issue><fpage>2034</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.058</pub-id><pub-id pub-id-type="other">2-s2.0-84896543725</pub-id><pub-id pub-id-type="pmid">24598723</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabynov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yespembetov</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ryskeldinova</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prime-booster vaccination of cattle with an influenza viral vector Brucella abortus vaccine induces a long-term protective immune response against Brucella abortus infection</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2016</year><volume>34</volume><issue>4</issue><fpage>438</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.12.028</pub-id><pub-id pub-id-type="other">2-s2.0-84952879000</pub-id><pub-id pub-id-type="pmid">26709638</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamal</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>York</surname><given-names>I. A.</given-names></name></person-group><article-title>Molecular determinants of influenza virus pathogenesis in mice</article-title><source><italic toggle="yes">Current Topics in Microbiology and Immunology</italic></source><year>2014</year><volume>385</volume><fpage>243</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1007/82_2014_388</pub-id><pub-id pub-id-type="other">2-s2.0-84921478952</pub-id><pub-id pub-id-type="pmid">25038937</pub-id><pub-id pub-id-type="pmcid">PMC4618372</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tate</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Pickett</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Reading</surname><given-names>P. C.</given-names></name></person-group><article-title>Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>15</issue><fpage>7569</fpage><lpage>7580</lpage><pub-id pub-id-type="doi">10.1128/jvi.00291-10</pub-id><pub-id pub-id-type="other">2-s2.0-77954492854</pub-id><pub-id pub-id-type="pmid">20504924</pub-id><pub-id pub-id-type="pmcid">PMC2897615</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>I.-H.</given-names></name><name name-style="western"><surname>Fukuyama</surname><given-names>S.</given-names></name><etal/></person-group><article-title>In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2018</year><volume>115</volume><issue>28</issue><fpage>E6622</fpage><lpage>E6629</lpage><pub-id pub-id-type="doi">10.1073/pnas.18062651155</pub-id><pub-id pub-id-type="pmid">29941581</pub-id><pub-id pub-id-type="pmcid">PMC6048509</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Visualizing influenza virus infection in living mice</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2013</year><volume>4</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/ncomms3369</pub-id><pub-id pub-id-type="other">2-s2.0-84893354829</pub-id><pub-id pub-id-type="pmcid">PMC3778511</pub-id><pub-id pub-id-type="pmid">24022374</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belyakov</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Ahlers</surname><given-names>J. D.</given-names></name></person-group><article-title>What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2009</year><volume>183</volume><issue>11</issue><fpage>6883</fpage><lpage>6892</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901466</pub-id><pub-id pub-id-type="other">2-s2.0-73349104433</pub-id><pub-id pub-id-type="pmid">19923474</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grill&#243;</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Gorvel</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Moriy&#243;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>E.</given-names></name></person-group><article-title>What have we learned from brucellosis in the mouse model?</article-title><source><italic toggle="yes">Veterinary Research</italic></source><year>2012</year><volume>43</volume><issue>1</issue><fpage>p. 29</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-43-29</pub-id><pub-id pub-id-type="other">2-s2.0-84864780098</pub-id><pub-id pub-id-type="pmcid">PMC3410789</pub-id><pub-id pub-id-type="pmid">22500859</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richt</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Attenuated influenza virus vaccines with modified NS1 proteins</article-title><source><italic toggle="yes">Current Topics in Microbiology and Immunology</italic></source><year>2009</year><volume>333</volume><fpage>177</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1007/978-3-540-92165-39</pub-id><pub-id pub-id-type="pmid">19768406</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilbourne</surname><given-names>E. D.</given-names></name></person-group><article-title>Influenza pandemics of the 20th century</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2006</year><volume>12</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3201/eid1201.051254</pub-id><pub-id pub-id-type="other">2-s2.0-31344448218</pub-id><pub-id pub-id-type="pmid">16494710</pub-id><pub-id pub-id-type="pmcid">PMC3291411</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bartrand</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Omura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>C. N.</given-names></name></person-group><article-title>Dose-response assessment for influenza A virus based on data sets of infection with its live attenuated reassortants</article-title><source><italic toggle="yes">Risk Analysis</italic></source><year>2012</year><volume>32</volume><issue>3</issue><fpage>555</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1111/j.1539-6924.2011.01680.x</pub-id><pub-id pub-id-type="other">2-s2.0-84858296192</pub-id><pub-id pub-id-type="pmid">21977924</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Percentages of body weight change of mice after prime-booster immunization. Percentages of body weight change of mice in experimental and control (after single vaccination with <italic toggle="yes">B. melitensis</italic> Rev.1 or administration of PBS) groups recorded daily 28 days after prime (a) and booster (b) immunization with mono-, bi-, or tetravalent formulations of rIVVs. Statistical analysis was performed with one-way ANOVA followed by Dunnett's multiple comparison test showed that during the 28 days, body weight measurement between the PBS control and vaccinated groups was not significant. <italic toggle="yes">P</italic> &lt; 0.05 values were considered significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BMRI2020-1438928.001.jpg"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Protectiveness of vaccine samples in guinea pigs estimated by the amount allocated to <italic toggle="yes">Brucella</italic> from tissues and organs (a) and index of infection (b). Animals were vaccinated at regime of prime-boost at interval of 21 days with mono-, bi-, or tetravalent vaccine formulations or a single delivery of commercial vaccine <italic toggle="yes">B. melitensis</italic> Rev.1. Guinea pigs in the negative control group were delivered with PBS. The challenge of animals was performed with virulent strain of <italic toggle="yes">B. melitensis</italic> 16M at a dose of 1.3 log<sub>10</sub> CFU/animal using an <italic toggle="yes">s.c.</italic> route. Bacteriological evaluation was assessed by counting <italic toggle="yes">Brucella</italic> colonies in tissues, where data is expressed as log<sub>10</sub> CFU/g and the index of infection in animals (the arithmetic mean &#177; standarderror was given for each group; number of tissues from where <italic toggle="yes">Brucella</italic> was isolated for each animal). Statistical analysis for (a) was performed using a one-way ANOVA followed by Tukey's multiple comparison test, and for (b) two-way ANOVA followed by Sidak's multiple comparison test. From <sup>&#8727;</sup><italic toggle="yes">P</italic> = 0.01 to <italic toggle="yes">P</italic> = 0.04; from <sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> = 0.002 to <italic toggle="yes">P</italic> = 0.004; from <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> = 0.0002 to <italic toggle="yes">P</italic> = 0.0007; <sup>&#8727;&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BMRI2020-1438928.002.jpg"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Scheme of immunization of animals.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Species</th><th align="center" rowspan="1" colspan="1">Viral construct</th><th align="center" rowspan="1" colspan="1">Prime vaccination dose (log<sub>10</sub> EID<sub>50</sub>/animal)</th><th align="center" rowspan="1" colspan="1">Booster vaccination dose (log<sub>10</sub> EID<sub>50</sub>/animal)</th></tr></thead><tbody><tr><td align="left" rowspan="9" colspan="1">Mice<break/><italic toggle="yes">i.p.</italic></td><td align="center" rowspan="1" colspan="1">Monovalent vaccine formulation (VF)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">(1) Flu-NS1-80-Omp16</td><td align="center" rowspan="1" colspan="1">(1) 6.14</td><td align="center" rowspan="1" colspan="1">(1) 6.22</td></tr><tr><td align="center" rowspan="1" colspan="1">(2) Flu-NS1-80-L7/L12</td><td align="center" rowspan="1" colspan="1">(2) 6.06</td><td align="center" rowspan="1" colspan="1">(2) 6.14</td></tr><tr><td align="center" rowspan="1" colspan="1">(3) Flu-NS1-80-Omp19</td><td align="center" rowspan="1" colspan="1">(3) 6.64</td><td align="center" rowspan="1" colspan="1">(3) 6.56</td></tr><tr><td align="center" rowspan="1" colspan="1">(4) Flu-NS1-80-SOD</td><td align="center" rowspan="1" colspan="1">(4) 6.56</td><td align="center" rowspan="1" colspan="1">(4) 6.22</td></tr><tr><td align="center" rowspan="1" colspan="1">(5) Flu-NS1-124-Omp16</td><td align="center" rowspan="1" colspan="1">(5) 6.64</td><td align="center" rowspan="1" colspan="1">(5) 6.56</td></tr><tr><td align="center" rowspan="1" colspan="1">(6) Flu-NS1-124-L7/L12</td><td align="center" rowspan="1" colspan="1">(6) 6.69</td><td align="center" rowspan="1" colspan="1">(6) 6.64</td></tr><tr><td align="center" rowspan="1" colspan="1">(7) Flu-NS1-124-Omp19</td><td align="center" rowspan="1" colspan="1">(7) 6.22</td><td align="center" rowspan="1" colspan="1">(7) 6.31</td></tr><tr><td align="center" rowspan="1" colspan="1">(8) Flu-NS1-124-SOD</td><td align="center" rowspan="1" colspan="1">(8) 6.31</td><td align="center" rowspan="1" colspan="1">(8) 6.56</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="9" colspan="1">Mice<break/><italic toggle="yes">i.p.</italic></td><td align="center" rowspan="1" colspan="1">Bivalent VF</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">(9) Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12</td><td align="center" rowspan="1" colspan="1">(9) 5.84 + 5.76</td><td align="center" rowspan="1" colspan="1">(9) 5.92 + 5.84</td></tr><tr><td align="center" rowspan="1" colspan="1">(10) Flu-NS1-80-Omp19+Flu-NS1-80-SOD</td><td align="center" rowspan="1" colspan="1">(10) 6.34 + 6.26</td><td align="center" rowspan="1" colspan="1">(10) 6.26 + 5.92</td></tr><tr><td align="center" rowspan="1" colspan="1">(11) Flu-NS1-80-Omp16+Flu-NS1-80-Omp19</td><td align="center" rowspan="1" colspan="1">(11) 5.84 + 6.34</td><td align="center" rowspan="1" colspan="1">(11) 5.92 + 6.26</td></tr><tr><td align="center" rowspan="1" colspan="1">(12) Flu-NS1-80-L7/L12+Flu-NS1-80-SOD</td><td align="center" rowspan="1" colspan="1">(12) 5.76 + 6.26</td><td align="center" rowspan="1" colspan="1">(12) 5.84 + 5.92</td></tr><tr><td align="center" rowspan="1" colspan="1">(13) Flu-NS1-124-Omp16+Flu-NS1-124-L7/L12</td><td align="center" rowspan="1" colspan="1">(13) 6.34 + 6.39</td><td align="center" rowspan="1" colspan="1">(13) 6.26 + 6.34</td></tr><tr><td align="center" rowspan="1" colspan="1">(14) Flu-NS1-124-Omp19+Flu-NS1-124-SOD</td><td align="center" rowspan="1" colspan="1">(14) 5.92 + 6.01</td><td align="center" rowspan="1" colspan="1">(14) 6.01 + 6.26</td></tr><tr><td align="center" rowspan="1" colspan="1">(15) Flu-NS1-124-Omp16+Flu-NS1-124-Omp19</td><td align="center" rowspan="1" colspan="1">(15) 6.34 + 5.92</td><td align="center" rowspan="1" colspan="1">(15) 6.26 + 6.01</td></tr><tr><td align="center" rowspan="1" colspan="1">(16) Flu-NS1-124-L7/L12+Flu-NS1-124-SOD</td><td align="center" rowspan="1" colspan="1">(16) 6.39 + 6.01</td><td align="center" rowspan="1" colspan="1">(16) 6.34 + 6.26</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Mice<break/><italic toggle="yes">i.p.</italic></td><td align="center" rowspan="1" colspan="1">Tetravalent VF</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">(17) Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD</td><td align="center" rowspan="1" colspan="1">(17) 5.54 + 5.46 + 6.04 + 5.96</td><td align="center" rowspan="1" colspan="1">(17) 5.62 + 5.54 + 5.96 + 5.62</td></tr><tr><td align="center" rowspan="1" colspan="1">(18) Flu-NS1-124-Omp16+Flu-NS1-124-L7/L12+Flu-NS1-124-Omp19+Flu-NS1-124-SOD</td><td align="center" rowspan="1" colspan="1">(18) 6.04 + 6.09 + 5.62 + 5.71</td><td align="center" rowspan="1" colspan="1">(18) 5.96 + 6.04 + 5.71 + 5.96</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="5" colspan="1">Guinea pigs<sup>&#8727;</sup><break/><italic toggle="yes">i.n.</italic></td><td align="center" rowspan="1" colspan="1">(1) Flu-NS1-80-Omp16</td><td align="center" rowspan="1" colspan="1">(1) 6.75</td><td align="center" rowspan="1" colspan="1">(1) 6.83</td></tr><tr><td align="center" rowspan="1" colspan="1">(8) Flu-NS1-124-SOD</td><td align="center" rowspan="1" colspan="1">(8) 6.92</td><td align="center" rowspan="1" colspan="1">(8) 7.04</td></tr><tr><td align="center" rowspan="1" colspan="1">(15) Flu-NS1-124-Omp16+Flu-NS1-124-Omp19</td><td align="center" rowspan="1" colspan="1">(15) 6.95 + 6.53</td><td align="center" rowspan="1" colspan="1">(15) 6.87 + 6.62</td></tr><tr><td align="center" rowspan="1" colspan="1">(17) Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD</td><td align="center" rowspan="1" colspan="1">(17) 6.14 + 6.06 + 6.64 + 6.56</td><td align="center" rowspan="1" colspan="1">(17) 6.22 + 6.14 + 6.56 + 6.22</td></tr><tr><td align="center" rowspan="1" colspan="1">(18) Flu-NS1-124-Omp16+Flu-NS1-124-L7/L12+Flu-NS1-124-Omp19+Flu-NS1-124-SOD</td><td align="center" rowspan="1" colspan="1">(18) 6.64 + 6.69 + 6.22 + 6.31</td><td align="center" rowspan="1" colspan="1">(18) 6.56 + 6.64 + 6.31 + 6.56</td></tr></tbody></table><table-wrap-foot><fn><p>Table note: number of animals per viral construct vaccine formulation for mice was 5 or 12 and for guinea pigs was 5 per group. The amounts of substance for mice via intraperitoneal (<italic toggle="yes">i.p.</italic>) were 500&#8201;<italic toggle="yes">&#956;</italic>l, and for guinea pigs, intranasal (<italic toggle="yes">i.n</italic>.) immunization was 200&#8201;<italic toggle="yes">&#956;</italic>l in both nostrils. <sup>&#8727;</sup>After the evaluation of protective efficacy of 18 vaccine formulations in mice, the 5 most protective vaccine formulations were selected and then tested in guinea pigs.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Level of protective efficacy of vaccines assessed by the isolation rate of <italic toggle="yes">Brucella</italic> from the spleens of mice challenged with the virulent strain <italic toggle="yes">B. melitensis</italic> 16M.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups</th><th align="center" rowspan="2" colspan="1">Vaccine samples</th><th align="center" rowspan="2" colspan="1">No. of animals</th><th align="center" rowspan="2" colspan="1">Brucella titer, log<sub>10</sub> CFU/g spleen (mean &#177; SE)</th><th align="center" rowspan="2" colspan="1">Protection unit (log<sub>10</sub>)<sup>&#8727;</sup></th><th align="center" colspan="2" rowspan="1">Significance to control group</th></tr><tr><th align="center" rowspan="1" colspan="1">(+) control</th><th align="center" rowspan="1" colspan="1">(-) control</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">80-Omp16</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.08 &#177; 0.86</td><td align="center" rowspan="1" colspan="1">2.79<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">80-L7/L12</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.7 &#177; 0.33</td><td align="center" rowspan="1" colspan="1">2.17</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">80-Omp19</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.68 &#177; 0.37</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">80-SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.64 &#177; 0.38</td><td align="center" rowspan="1" colspan="1">2.24</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">124-Omp16</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.41 &#177; 0.84</td><td align="center" rowspan="1" colspan="1">2.46</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">124-L7/L12</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.47 &#177; 0.55</td><td align="center" rowspan="1" colspan="1">2.40</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">124-Omp19</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4.1 &#177; 0.29</td><td align="center" rowspan="1" colspan="1">1.78</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">124-SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.2 &#177; 0.76</td><td align="center" rowspan="1" colspan="1">2.60<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">80-Omp16+L7/L12</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.78 &#177; 0.41</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">80-Omp19+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4.18 &#177; 0.3</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">80-Omp16+Omp19</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.83 &#177; 0.39</td><td align="center" rowspan="1" colspan="1">2.04</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">80-L7/L12+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.57 &#177; 0.28</td><td align="center" rowspan="1" colspan="1">2.30</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">80-Omp16+L7/L12+Omp19+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.13 &#177; 0.25</td><td align="center" rowspan="1" colspan="1">2.75<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">124-Omp16+L7/L12</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.49 &#177; 0.36</td><td align="center" rowspan="1" colspan="1">2.38</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">124-Omp19+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.64 &#177; 0.53</td><td align="center" rowspan="1" colspan="1">2.23</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">124-Omp16+Omp19</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.18 &#177; 0.69</td><td align="center" rowspan="1" colspan="1">2.69<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">124-L7/L12+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4.27 &#177; 0.3</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">124-Omp16+L7/L12+Omp19+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.17 &#177; 0.38</td><td align="center" rowspan="1" colspan="1">2.70<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">B. melitensis</italic> Rev.1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.20 &#177; 0.31</td><td align="center" rowspan="1" colspan="1">2.68<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">Control (PBS)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5.88 &#177; 0.16</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot><fn><p>Table legend: <sup>&#8727;</sup>log<sub>10</sub> protection units were obtained by subtracting the mean log<sub>10</sub> CFU of the control (PBS) group from the mean of log<sub>10</sub> CFU for the experimental group and for the positive control group. (+) control: animals vaccinated with <italic toggle="yes">B. melitensis</italic> Rev.1 commercial vaccine. (-) control: animals inoculated with PBS. <sup>&#8727;</sup>alpha = 0.02&#8208;0.01 vs. PBS control group, <italic toggle="yes">B. melitensis</italic> Rev.1 vs. vaccine groups. Statistical analysis was performed using a one-way ANOVA (Tukey's multiple comparison test).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Rates of protection in guinea pigs after challenge with the virulent strain <italic toggle="yes">B. melitensis</italic> 16M.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Immunization group</th><th align="center" rowspan="2" colspan="1">Total animals</th><th align="center" rowspan="2" colspan="1">Isolation of <italic toggle="yes">B. melitensis</italic> in animals, <italic toggle="yes">n</italic> (%)</th><th align="center" colspan="2" rowspan="1">Value (<italic toggle="yes">P</italic>)<sup>&#8727;</sup></th></tr><tr><th align="center" rowspan="1" colspan="1">(+) control</th><th align="center" rowspan="1" colspan="1">(-) control</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">80-Omp16</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">80-Omp16+L7/L12+Omp19+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1 (20)</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">124-SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">124-Omp16+Omp19</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">124-Omp16+L7/L12+Omp19+SOD</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td><td align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. melitensis</italic> Rev.1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1 (20)</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Control (PBS)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5(100)</td><td align="center" rowspan="1" colspan="1">&lt;0.05</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot><fn><p>Table note: <sup>&#8727;</sup>in comparison with control untreated PBS or <italic toggle="yes">B. melitensis</italic> Rev.1 groups. Statistical analysis was performed using a one-sided Fisher's exact test. &lt;0.05: <italic toggle="yes">P</italic> value less than 0.05; &gt;0.05: <italic toggle="yes">P</italic> value higher than 0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>